TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06769854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgent PC
Description: PTNS is a technique of electrical neuromodulation used primarily for treating OAB. The procedure for PTNS consists of the insertion of a fine needle above the medial malleolus near the posterior tibial nerve followed by the application of low-voltage electrical stimulation that produces sensory and motor responses.
Study: NCT06765733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleeto
Description: Aleeto is a nerve repair protein developed by Darwin Start (Beijing) Biopharmaceutical Co., Ltd. It is a group of specific microenvironmental protein polymers secreted under the emergency conditions of stem cells. It has the advantages of selective assembly, targeted delivery, efficient repair of damaged tissues, high safety, chemical stability, easy storage, etc., and has a powerful neural repair function. According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection.
Study: NCT06768801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WPAPP-Latina
Description: The WPAPP Latina intervention provides 1) educational information via modules and online resources and 2) coaching via an online forum with a chat function. The educational modules include 11 modules on physical activity promotion and 7 modules on depressive symptoms. The women are also invited to share their experiences with culturally matched interventionists (e.g., Spanish speaking graduate research assistant with expertise in depressive symptoms and physical activity) and with peer participants using a de-identified name in the online chat forum. Participants will be directed to information about physical activity with age-appropriate guidelines from the Centers for Disease Control and Prevention.
Study: NCT06765954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 (IL-15 Superagonist)
Description: Administered subcutaneously (SC) both before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETBX-071 (PSA-based Oncolytic Virus)
Description: Administered subcutaneously (SC) before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-CENK (Activated NK Cells)
Description: Administered intravenously (IV) before and after radiation therapy, also with variations in the timing and dosing across different cohorts.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Description: This is a standard treatment administered to all participants. The specific dose and schedule (40 Gy in 5 fractions over 2 weeks or up to 9 weeks) are determined by the investigator based on clinical judgment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: May be used in conjunction with the other therapies. The specific type and duration of ADT are at the investigator's discretion, and it may be initiated up to 6 months after the completion of radiotherapy. This treatment is not part of the experimental treatment regimen.
Study: NCT04796506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training (ET)
Description: Non-responders to PRT will transition too ET during 2nd 12 weeks of the study. This intervention is supervised endurance training, 3 times per week for 12 weeks. Each session lasts approximately 75 min., comprised of warm-up, stimulus phase for 50-60 min., and cool-down. Sessions are split between cycle ergometer and treadmill exercise. Participant heart rate is monitored to maintain target exercise intensity of 60-80% (±5%) of heart rate reserve (HRR).
Study: NCT06765954

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-radiation immunotherapy
Description: The post-radiation immunotherapy phase in the ResQ110B-PROS study involves the continued administration of N-803, ETBX-071, and M-CENK, but with a specific schedule and after the completion of radiation therapy.
Study: NCT05737706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX1133
Description: KRAS G12D Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX1133
Description: KRAS G12D Inhibitor
Study: NCT02998229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artisse™ Intrasaccular Device
Description: Intrasaccular Device
Study: NCT05943106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab via intravenous infusion from Week 1 for 13 cycles every 4 weeks (q4w) for maximum 12 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Participants will receive BCG via intravesical as induction weekly for 6 weeks starting at Week 1, Day 1 and subsequently for maintenance for 3 weekly doses up to 3, 6, 12, 18, and 24 months, at the physician's discretion as Standard of care.
Study: NCT06653465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen, which has similarly effects with NSAIDs in terms of inhibition of cyclooxygenase COX1, COX2 and COX3, is widely used as adjuvant for perioperative multimodal analgesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, a kind of crystalloid widely used in clinical treatment.
Study: NCT06062238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine
Description: Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive an intramuscular dose of normal saline (0.9 percent \[%\] sodium chloride \[NaCl\]), on Day 1 and Day 29.
Study: NCT05200572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Life Review (DLR)
Description: DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
Study: NCT06514742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant
Description: Aticaprant tablet will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study: NCT05335941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Given by vein (IV)
Study: NCT06648031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 - DehydraTECH-CBD alone
Description: Dose: 250 mg CBD twice daily (500 mg/day) for 12 weeks. Route of administration: Oral Dosage form: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2 - DehydraTECH-semaglutide alone
Description: Dose: 3.5 mg once daily for 4 weeks, ascending to 7 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
Description: DehydraTECH-CBD dosing = 250 mg twice daily for 12 weeks.~- DehydraTECH-semaglutide = 3.5 mg once daily for 12 weeks Route of administration: Oral Dosage form: Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 4 - Rybelsus medication (semaglutide) alone
Description: Normal clinical dose of 3.0 mg once daily for 4 weeks, ascending to 7.0 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
Study: NCT05335941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Given by PO
Study: NCT05355792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OmniTaper EV implants
Description: Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
Study: NCT05279222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait adaptability training
Description: All patients will receive two gait training interventions, each consisting of twelve one hour training sessions. The training sessions will be focussed on improving gait capacity.
Study: NCT05398380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Liver transplantation
Study: NCT04854005

Intervention type: PROCEDURE
Intervention: Breast surgery
Description: Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
Study: NCT04525547

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study: NCT06434402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Write about cancer experiences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Write about cancer experiences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Write about cancer experiences
Study: NCT05995080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clorhexidine gluconate bathing
Description: daily skin cleansing with chlorhexidine gluconate
Study: NCT05742009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare ST500
Description: Measurement of Intraocular Pressure (IOP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAT
Description: Measurement of Intraocular Pressure (IOP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare IC200
Description: Measurement of Intraocular Pressure (IOP)
Study: NCT06662864

Intervention type: OTHER
Intervention: Patients reported outcomes
Description: Patients reported outcomes were collected via telephone

Intervention type: OTHER
Intervention: questionnaire global Pittsburgh Sleep Quality Index (PSQI)
Description: Patients reported outcomes were collected via telephone
Study: NCT06666543

Intervention type: OTHER
Intervention: Questionary
Description: The questionnaire will address the following topics for each child who is not infected with HIV and was born to an infected mother at the time of birth:~* Pregnancy progression~* Immediate postpartum course~* Medical development of the child from 0 to 3 years~* Medical development of the child from 3 to a maximum of 15 years
Study: NCT06508801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: The BFR Intervention will consist of 75 repetitions; reps (set 1: 30 reps, sets 2 - 4: 15 reps with 30 s of rest between sets and 1 minute between exercises) at 20-30% of 10 repetition maximum (RM). BFR training will be performed during toe raises, lunges and single leg stance exercises on unstable surfaces (i.e., foam, Dyna disc, balance disc, and BOSU-ball®) as tolerated by the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability Resistance Training
Description: The following devices will be used for instability training: foam, dyna disc, balance disc and BOSU-ball®. Unstable devices will be changed during the six-week period from the least to the most unstable devices. Once a participant reduces the body sway on a device, the device will be progressed. Participants will perform IRT with or without blood flow restriction.

Intervention type: OTHER
Group type: OTHER
Intervention: Instability Resistance Training
Description: The following devices will be used for instability training: foam, dyna disc, balance disc and BOSU-ball®. Unstable devices will be changed during the six-week period from the least to the most unstable devices. Once a participant reduces the body sway on a device, the device will be progressed. Participants will perform IRT with or without blood flow restriction.
Study: NCT05751031

Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
Study: NCT05492773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations Technique
Description: Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active comparater
Description: Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
Study: NCT06235658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Yoga
Description: Participants will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks. Each session will be conducted via videoconference using the Zoom platform, with participants joining from their homes.
Study: NCT06233643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phloroglucinol
Description: The active comparators will be treated with 40 mg of Phloroglucinol in the form of a single intramuscular injection.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acupuncture Combined Intradermal Sterile Water
Description: Acupuncture was applied to a seated patient using the urinary bladder meridian points and combianed Intradermal Sterile Water in costovertebral area where the patient's pain was located (Sterile water of 0.5 ml was injected as intradermal into 4 points at a depth of 1-3 mm to form papules)
Study: NCT04436458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Oral Tablet
Description: Continued SOC therapy together with niclosamide TID for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
Study: NCT06365307

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Osteoplastic material based on octacalcium phosphate and biologically active nucleic acids for bone tissue regeneration Nucleostim-VEGF (Histograft)
Description: Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic osteoplastic material based on β-TCP or bone autograft
Description: Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
Study: NCT05974995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Description: Total hysterectomy with bilateral salpingo-oophorectomy and lymphnodes staging using DaVinci Xi

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Total hysterectomy with bilateral salpingo-oophorectomy and lymph nodes staging using standard laparoscopic approach
Study: NCT04595682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
Study: NCT06666166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Apartinib
Description: SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Apartinib
Description: SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.
Study: NCT06664931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group (A) Muscle Energy Technique (MET)
Description: MET will be applied to three key muscles commonly associated with neck pain:~upper trapezius, levator scapulae, and anterior scalenus.
Study: NCT05561777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-targeted CDS tool for PCN allergy delabeling
Description: This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
Study: NCT04942301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use the vein pump to pump drugs
Description: During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use the vein pump to pump drugs
Description: During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination therapy
Description: Combination therapy with chemotherapy drugs was used

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination therapy
Description: Combination therapy with chemotherapy drugs was used
Study: NCT05781139

Intervention type: DIAGNOSTIC_TEST
Intervention: levels of Neurofilaments (NfL) in serum
Description: the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: levels of Neurofilaments (NfL) in serum
Description: the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: levels of Neurofilaments (NfL) in serum
Description: the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: levels of Neurofilaments (NfL) in serum
Description: the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
Study: NCT06122220

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ONSD+AF
Description: Measurement of the optic nerve sheath diameter and of sFLT-1/PGIF index

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ONSD+AF
Description: Measurement of the optic nerve sheath diameter and of sFLT-1/PGIF index
Study: NCT06664931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group (B) Mulligan Mobilizations Techniques (MMT).
Description: Participants in Group (B) will receive MMT alongside the traditional treatment. MMT utilizes a specific technique called Sustained Natural Apophyseal Glides (SNAGs) to improve joint mobilization.
Study: NCT06666686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active noise control headphone
Description: This is the group where active noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
Study: NCT04773457

Intervention type: OTHER
Intervention: Surgical Site Infection
Description: infection at the site of the surgery (spine or abdomen)

Intervention type: OTHER
Intervention: Surgical Site Infection
Description: infection at the site of the surgery (spine or abdomen)
Study: NCT06666686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive noise control headphone
Description: This is the group where passive noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
Study: NCT06665750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A progressive upper extremity neuromuscular exercise program was performed face to face with the researcher physiotherapist for the study group. The exercise program was applied for approximately 20 minutes, 2 days a week for 6 weeks, on the same days of the week, before the participants' tennis training. The exercise content and number of repetitions in the training program changed every 2 weeks with increasing difficulty.